Entrada Therapeutics, Inc. - 8-K Filing
Entrada Therapeutics reported positive safety and dystrophin production results from the first cohort in its Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 for Duchenne Muscular Dystrophy. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $TRDA